{
    "nct_id": "NCT00165724",
    "title": "Alzheimer's Disease Long-term Follow-up Study (ALF Study)",
    "status": "COMPLETED",
    "last_update_time": "2021-12-10",
    "description_brief": "Open study for efficacy and safety of donepezil treatment during 48 weeks",
    "description_detailed": "N/A",
    "phase": [
        "PHASE4"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "cognitive enhancer",
    "drug": [
        "donepezil (Aricept)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests donepezil, a centrally acting, reversible acetylcholinesterase inhibitor (small\u2011molecule drug) given to people with Alzheimer\u2019s disease to improve/maintain cognition and global function rather than to target amyloid/tau pathology or alter disease biology. \ue200cite\ue202turn1search4\ue202turn1search2\ue201",
        "Act: Extracted details \u2014 drug: donepezil (brand Aricept); intervention type: oral small molecule acetylcholinesterase inhibitor; intended effect in AD: symptomatic cognitive improvement and maintenance (efficacy and safety assessed over long-term/open\u2011label follow\u2011up). Long-term open\u2011label studies have evaluated donepezil for many months to years (e.g., 48\u2013132 weeks or longer) showing maintained cognitive benefits and safety monitoring in extension studies. \ue200cite\ue202turn1search2\ue202turn0search4\ue202turn0search6\ue201",
        "Web search results (key sources found): 1) Donepezil evidence review / symptomatic use in AD (PMC review). \ue200cite\ue202turn1search4\ue201 2) Aricept (donepezil) Prescribing Information / FDA package insert (indications, dosing, safety). \ue200cite\ue202turn1search2\ue201 3) Long-term open\u2011label efficacy/safety studies of donepezil (US multicenter open\u2011label extension analyses). \ue200cite\ue202turn0search4\ue202turn0search1\ue201 4) Reviews/meta-analyses showing cognitive benefits vs placebo in trials. \ue200cite\ue202turn0search7\ue201",
        "Reflect: Classification check \u2014 fits the definition of 'Cognitive enhancer' (small\u2011molecule symptomatic treatment that improves cognition), not a biologic and not primarily aimed at neuropsychiatric/agitation symptoms nor a diagnostic procedure. No indication in the description that donepezil is being used as a disease\u2011modifying agent, so 'cognitive enhancer' is the appropriate category. \ue200cite\ue202turn1search4\ue202turn1search2\ue201"
    ],
    "agent_type": "D) Neurotransmitter Receptors",
    "explanation_agent": [
        "Reason: The trial tests donepezil (Aricept), a centrally acting, reversible acetylcholinesterase inhibitor that increases synaptic acetylcholine to produce symptomatic cognitive improvement rather than targeting amyloid or tau pathology. \ue200cite\ue202turn0search3\ue202turn0search8\ue201",
        "Act: Extracted details \u2014 drug: donepezil (Aricept); intervention type: oral small\u2011molecule acetylcholinesterase (AChE) inhibitor; intended effect in AD: symptomatic cognitive and global-function improvement and long\u2011term safety/efficacy follow\u2011up (open\u2011label extensions up to ~132\u2013144 weeks reported). \ue200cite\ue202turn0search6\ue202turn0search0\ue202turn0search1\ue201",
        "Reflect: Classification check \u2014 this intervention modulates cholinergic neurotransmission (a neurotransmitter system) and is not described as disease\u2011modifying or targeting amyloid/tau, so the most specific CADRO match is D) Neurotransmitter Receptors. Not multi-target or non\u2011therapeutic. \ue200cite\ue202turn0search8\ue201",
        "Web search results (key sources): 1) Donepezil: Cochrane/clinical review and evidence of symptomatic benefits. \ue200cite\ue202turn0search3\ue201 2) Donepezil long\u2011term extension trials and open\u2011label studies (144\u2011week US extension). \ue200cite\ue202turn0search6\ue201 3) 132\u2011week open\u2011label multicentre study of long\u2011term efficacy/safety. \ue200cite\ue202turn0search0\ue201 4) Donepezil review describing mechanism as a selective, reversible AChE inhibitor and clinical effects. \ue200cite\ue202turn0search2\ue202turn0search8\ue201"
    ]
}